Design of Nanoparticles for Immunotherapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: closed (10 October 2021) | Viewed by 3456
Special Issue Editors
Interests: nanoparticles mediated delivery of therapeutic drug and genes; bio-compatible hydrogels
Special Issues, Collections and Topics in MDPI journals
Interests: nanoparticle; nanotechnology; adjuvant; nanovaccinology; polymeric vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer and virus or bacteria infection are the leading causes of death globally. Even though chemotherapy is a commonly used therapeutic clinical strategy to treat the diseases, its effectiveness is limited due to a steep dose–response relationship, narrow therapeutic window, and non-specific organ toxicity. Therefore, there is a demand for developing more effective therapeutic strategies. Preclinical findings regarding adaptive immune therapy are very impressive, but little success has been obtained so far in translating effectively these results into the clinic. One major reason for this is the highly complex immune systems. The immune-suppressive properties of tumor and virus or bacteria infection prevent anti-immune effector cells from acting against related cells. Recent advances in science and technology have led to the development of a variety of delivery systems such as nanoparticles capable of generating robust balanced immune responses. These systems are responsive to variations in pH, redox potential, enzymatic activation, thermal gradients, magnetic fields, light, ultrasound and biological conditions. These systems can even be tailored to be responsive to dual or multiple stimuli. Topics of interest to this Special Issue include natural and biomimetic microenvironment-responsive particles for immunotherapy, anti-tumor immunity-eliciting nanoparticles, and related concepts.
Prof. Dr. In-Kyu Park
Prof. Dr. Chong-Su Cho
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Polymeric nanoparticles for immunotherapy
- Tumor microenvironment-responsive immunotherapeutic nanoparticles
- External and internal stimuli-responsive nanoparticles for immunotherapy
- Combinational anti-cancer vaccine therapy and immunotherapy
- Tumor microenvironment-remodeling immunotherapeutic nanoparticles
